{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    46,
    48,
    49,
    50,
    51,
    52,
    69,
    70,
    71,
    90
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "The day of the first vaccination (Vaccination 1)",
        "anchorType": "Day1",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 80,
        "sourceText": "Visit Number 1, Visit Description Vaccination 1, Visit Window (Days) Day 1",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_1",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "42 Days After"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "196 Days After"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "7 days after"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "10 days after"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "42 days after"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "42 Days \nAfter"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "196 Days \nAfter"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "28 days after"
      },
      {
        "id": "rep_window_22",
        "type": "Continuous",
        "sourceText": "42 Days\nAfter"
      },
      {
        "id": "rep_window_46",
        "type": "Continuous",
        "sourceText": "28 days before"
      },
      {
        "id": "rep_window_47",
        "type": "Continuous",
        "sourceText": "60 days before"
      },
      {
        "id": "rep_window_48",
        "type": "Continuous",
        "sourceText": "48 hours before"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P42D",
        "interval": "P28D",
        "minObservations": 2,
        "exitCondition": "Completion of Vaccination 2",
        "sourceText": "Cohort 1: Visit 2 (Vaccination 2 – 28 to 42 Days After Visit 1)"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P168D",
        "endOffset": "P196D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "Completion of 6-Month Safety Collection",
        "sourceText": "6-Month Safety Collection [Telephone Contact] – 168 to 196 Days After Vaccination 1"
      },
      {
        "id": "rep_llm_3",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P1D",
        "minObservations": 7,
        "exitCondition": "End of diary reporting period",
        "sourceText": "7.2.1. Subject Electronic Diary"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "VACCINATION_1",
          "VACCINATION_2_OR_FOLLOW_UP",
          "IMMUNOGENICITY_FOLLOW_UP",
          "END_OF_STUDY_TELEPHONE_CONTACT"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Visit 2 (Day 28-42)",
          "Day 1",
          "Visit 4 (6-Month Telephone Contact)",
          "Visit 1 (Day 1)",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'Subject is in Cohort 1 (Age >= 60)', 'path': ['Visit 1 (Vaccination 1)', 'Visit 2 (Vaccination 2)', 'Visit 3 (Blood Draw)', 'Visit 4 (6-Month Follow-up)']}, {'condition': 'Subject is in Cohort 2 or 3 (Age 18-59)', 'path': ['Visit 1 (Vaccination 1)', 'Visit 2 (Blood Draw)', 'Visit 4 (6-Month Follow-up)']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Draw",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Diary",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Physical examination based on medical history",
        "executionType": "Single",
        "rationale": "The protocol describes this as a clinical assessment performed at the start of the study based on medical history."
      },
      {
        "activityId": "Temperature monitoring",
        "executionType": "Single",
        "rationale": "Table 7 and Section 7.2 describe temperature ranges and monitoring following vaccination, which typically involves a continuous daily window of collection."
      },
      {
        "activityId": "SAE reporting within 30 days",
        "executionType": "Single",
        "rationale": "The investigator must contact the sponsor if an SAE occurs; this is a conditional workflow triggered by a specific event."
      },
      {
        "activityId": "Immunogenicity bridging analysis",
        "executionType": "Single",
        "rationale": "This is a specific data analysis activity performed once to compare cohorts."
      },
      {
        "activityId": "Clinical assessment",
        "executionType": "Single",
        "rationale": "The Schedule of Activities and Amendment 1 notes indicate this is a repeated activity at study visits with added flexibility in wording."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "procedure_timepoints",
        "text": "a. Control group from enrollment and vaccination with 13vPnC at Visit 1 until vaccination with PPSV23 at Visit 2.",
        "footnoteId": "fn_1",
        "structuredCondition": "group == 'Control' && time >= Visit1 && time < Visit2",
        "appliesToActivityIds": [
          "13vPnC Vaccination"
        ],
        "sourceText": "a. Control group from enrollment and vaccination with 13vPnC at Visit 1 until vaccination with PPSV2"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "b. Control group after vaccination with PPSV23 at Visit 2.",
        "footnoteId": "fn_2",
        "structuredCondition": "group == 'Control' && time >= Visit2",
        "appliesToActivityIds": [
          "PPSV23 Vaccination"
        ],
        "sourceText": "b. Control group after vaccination with PPSV23 at Visit 2."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. SAEs and newly diagnosed chronic medical conditions (NDCMCs) will be collected through 6 months after Visit 1.",
        "footnoteId": "fn_3",
        "structuredCondition": "collection.duration(SAE, NDCMC) <= P6M",
        "appliesToActivityIds": [
          "SAE Collection",
          "NDCMC Collection"
        ],
        "sourceText": "c. SAEs and newly diagnosed chronic medical conditions (NDCMCs) will be collected through 6 months a"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "4. SUBJECT ELIGIBILITY CRITERIA This study can fulfill its objectives only if appropriate subjects are enrolled. The following eligibility criteria are designed to select subjects for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular subject is suitable for this protocol. Subject eligibility should be reviewed and documented by an appropriate member of the investigator’s study team before subjects are included in the study.",
        "footnoteId": "fn_4",
        "structuredCondition": "eligibility.review_status == 'documented'",
        "appliesToActivityIds": [
          "Subject Enrollment"
        ],
        "sourceText": "4. SUBJECT ELIGIBILITY CRITERIA This study can fulfill its objectives only if appropriate subjects a"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.",
        "footnoteId": "fn_5",
        "structuredCondition": "subject.has_signed_icd == true",
        "appliesToActivityIds": [
          "Informed Consent"
        ],
        "sourceText": "1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the sub"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "2. Willing and able to comply with scheduled visits, treatment plan, and other study procedures.",
        "footnoteId": "fn_6",
        "structuredCondition": "subject.compliance_willingness == true",
        "appliesToActivityIds": [
          "All Study Procedures"
        ],
        "sourceText": "2. Willing and able to comply with scheduled visits, treatment plan, and other study procedures."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "3. Expected to be available for the duration of the study and can be contacted by telephone during study participation.",
        "footnoteId": "fn_7",
        "structuredCondition": "subject.availability == true && subject.phone_contactable == true",
        "appliesToActivityIds": [
          "All Study Procedures"
        ],
        "sourceText": "3. Expected to be available for the duration of the study and can be contacted by telephone during s"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "5. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease,",
        "footnoteId": "fn_8",
        "structuredCondition": "subject.age_group == 'Adult' && subject.disease_status == 'stable'",
        "appliesToActivityIds": [
          "Enrollment"
        ],
        "sourceText": "5. Adults determined by clinical assessment, including medical history and clinical judgment, to be "
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_after",
        "text": "6. Cohort 1 only: Female subject of nonchildbearing potential or male subject not able to father children; male subject who is able to father children and willing to use a highly effective method of contraception as outlined in this protocol until at least 28 days after the last dose of investigational product. Cohorts 2 and 3 only: Female subject of childbearing potential or male subject who is able to father children, and willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.",
        "footnoteId": "fn_9",
        "structuredCondition": "(cohort == 1 && subject.fertility == false) || (cohort == 1 && subject.fertility == true && contraception.duration >= P28D) || (cohort.in([2,3]) && contraception.duration >= P28D)",
        "appliesToActivityIds": [
          "Enrollment"
        ],
        "sourceText": "6. Cohort 1 only: Female subject of nonchildbearing potential or male subject not able to father chi"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "7. History of microbiologically proven invasive disease caused by S pneumoniae.",
        "footnoteId": "fn_10",
        "structuredCondition": "subject.history.invasive_s_pneumoniae == true",
        "appliesToActivityIds": [
          "Enrollment"
        ],
        "sourceText": "7. History of microbiologically proven invasive disease caused by S pneumoniae."
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_before",
        "text": "8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, or planned receipt through the last blood draw. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.",
        "footnoteId": "fn_11",
        "structuredCondition": "subject.medication.immunosuppressive == false && (subject.medication.corticosteroids.short_term == true ? washout >= P28D : true)",
        "appliesToActivityIds": [
          "Enrollment",
          "Investigational Product Administration"
        ],
        "sourceText": "8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or syst"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "9. Subjects with known or suspected immunodeficiency or other conditions associated with immunosuppression, including, but not limited to, immunoglobulin class/subclass deficiencies, generalized malignancy, human immunodeficiency virus (HIV) infection, leukemia, lymphoma, or organ or bone marrow transplant.",
        "footnoteId": "fn_12",
        "structuredCondition": "subject.immunodeficiency == false && subject.malignancy == false && subject.hiv == false",
        "appliesToActivityIds": [
          "Enrollment"
        ],
        "sourceText": "9. Subjects with known or suspected immunodeficiency or other conditions associated with immunosuppr"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary Safety: Local Reactions",
        "endpointType": "Primary",
        "inputs": [
          "redness",
          "swelling",
          "pain at injection site"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P10D"
        },
        "algorithm": "count(reported_prompted_local_reactions)",
        "successCriteria": "Descriptive safety profile",
        "sourceText": "Reported prompted local reactions (redness, swelling, and pain at the injection site) within 10 days after vaccination."
      },
      {
        "id": "ep_2",
        "name": "Primary Safety: Systemic Events",
        "endpointType": "Primary",
        "inputs": [
          "fever",
          "headache",
          "fatigue",
          "muscle pain",
          "joint pain"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P7D"
        },
        "algorithm": "count(reported_prompted_systemic_events)",
        "successCriteria": "Descriptive safety profile",
        "sourceText": "Reported prompted systemic events (fever, headache, fatigue, muscle pain, and joint pain) within 7 days after vaccination."
      },
      {
        "id": "ep_3",
        "name": "Primary Immunogenicity: OPA Titers (Cohort 1)",
        "endpointType": "Primary",
        "inputs": [
          "serotype-specific OPA titers"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "Geometric Mean Titers (GMTs) comparison (20vPnC vs 13vPnC/PPSV23)",
        "successCriteria": "Noninferiority to 13vPnC (13 serotypes) and PPSV23 (7 additional serotypes)",
        "sourceText": "Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination."
      },
      {
        "id": "ep_4",
        "name": "Secondary Immunogenicity: OPA Titers (Cohort 2 & 3)",
        "endpointType": "Secondary",
        "inputs": [
          "serotype-specific OPA titers"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "Geometric Mean Titers (GMTs) comparison (Cohort 2/3 vs Cohort 60-64 years)",
        "successCriteria": "Noninferiority to immune responses induced by 20vPnC in adults 60 through 64 years of age",
        "sourceText": "Serotype-specific OPA titers 1 month after vaccination."
      },
      {
        "id": "ep_5",
        "name": "Secondary Immunogenicity: OPA Fold Rise",
        "endpointType": "Secondary",
        "inputs": [
          "OPA_titer_baseline",
          "OPA_titer_post_vaccination"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "OPA_titer_post_vaccination / OPA_titer_baseline",
        "successCriteria": "Descriptive immune response",
        "sourceText": "Fold rise in serotype-specific OPA titers from before to 1 month after vaccination."
      },
      {
        "id": "ep_6",
        "name": "Safety: Adverse Events (AEs)",
        "endpointType": "Primary",
        "inputs": [
          "Adverse Events"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "count(AEs)",
        "successCriteria": "Descriptive safety profile",
        "sourceText": "Reported adverse events (AEs) within 1 month after vaccination."
      },
      {
        "id": "ep_7",
        "name": "Safety: SAEs and NDCMCs",
        "endpointType": "Primary",
        "inputs": [
          "Serious Adverse Events",
          "Newly Diagnosed Chronic Medical Conditions"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P6M"
        },
        "algorithm": "count(SAEs) + count(NDCMCs)",
        "successCriteria": "Descriptive safety profile",
        "sourceText": "Reported serious adverse events (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Serotype-specific OPA GMTs",
        "variableType": "Custom",
        "sourceVariables": [
          "OPA titer"
        ],
        "derivationRule": "exp(mean(ln(OPA titers)))",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "1 month after each vaccination",
        "imputationRule": "Missing assay results will not be replaced or imputed. OPA titers below LLOQ handled per SAP.",
        "unit": "titer"
      },
      {
        "id": "dv_2",
        "name": "OPA GMR (20vPnC/saline to 13vPnC/PPSV23)",
        "variableType": "Custom",
        "sourceVariables": [
          "OPA titer"
        ],
        "derivationRule": "exp(mean(ln(20vPnC group)) - mean(ln(13vPnC/PPSV23 group)))",
        "baselineDefinition": "N/A (Comparison between groups)",
        "baselineVisit": "N/A",
        "analysisWindow": "Visit 2 (13 matched serotypes); Visit 2 vs Visit 3 (7 additional serotypes)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "ratio"
      },
      {
        "id": "dv_3",
        "name": "OPA GMFR",
        "variableType": "PercentChange",
        "sourceVariables": [
          "OPA titer"
        ],
        "derivationRule": "Geometric mean of the ratios of post-vaccination titer to pre-vaccination titer",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "Visit 1 to Visit 2 (20vPnC and 13vPnC matched); Visit 1 to Visit 3 (13vPnC/PPSV23 7 additional)",
        "imputationRule": "Limited to subjects with nonmissing values both before and after vaccination.",
        "unit": "ratio"
      },
      {
        "id": "dv_4",
        "name": "Proportion of subjects with OPA titers ≥LLOQ",
        "variableType": "Categorical",
        "sourceVariables": [
          "OPA titer",
          "LLOQ"
        ],
        "derivationRule": "(Count of subjects with titer >= LLOQ / Total subjects) * 100",
        "baselineDefinition": "Pre-vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "Visit 1, Visit 2, and Visit 3 (as applicable per serotype)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "%"
      },
      {
        "id": "dv_5",
        "name": "Proportion of subjects with ≥4-fold rise in OPA titer",
        "variableType": "Categorical",
        "sourceVariables": [
          "OPA titer"
        ],
        "derivationRule": "(Count of subjects with (Post-vaccination titer / Pre-vaccination titer) >= 4 / Total subjects) * 100",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "Visit 1 to Visit 2 (20vPnC and 13vPnC matched); Visit 1 to Visit 3 (13vPnC/PPSV23 7 additional)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "%"
      },
      {
        "id": "dv_6",
        "name": "OPA GMR (Age Bridging)",
        "variableType": "Custom",
        "sourceVariables": [
          "OPA titer"
        ],
        "derivationRule": "exp(mean(ln(Younger Cohort)) - mean(ln(Older Cohort)))",
        "baselineDefinition": "N/A (Comparison between age cohorts)",
        "baselineVisit": "N/A",
        "analysisWindow": "Visit 2 (1 month after vaccination)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "ratio"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Vaccination 1",
        "Vaccination 2 Or Follow Up",
        "Immunogenicity Follow Up",
        "End Of Study Telephone Contact",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Vaccination 1",
          "trigger": "Progress to Vaccination 1"
        },
        {
          "fromState": "Vaccination 1",
          "toState": "Vaccination 2 Or Follow Up",
          "trigger": "Progress to Vaccination 2 Or Follow Up"
        },
        {
          "fromState": "Vaccination 2 Or Follow Up",
          "toState": "Immunogenicity Follow Up",
          "trigger": "Progress to Immunogenicity Follow Up"
        },
        {
          "fromState": "Immunogenicity Follow Up",
          "toState": "End Of Study Telephone Contact",
          "trigger": "Progress to End Of Study Telephone Contact"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Vaccination 1": "VACCINATION_1",
        "Vaccination 2 Or Follow Up": "VACCINATION_2_OR_FOLLOW_UP",
        "Immunogenicity Follow Up": "IMMUNOGENICITY_FOLLOW_UP",
        "End Of Study Telephone Contact": "END_OF_STUDY_TELEPHONE_CONTACT",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "20-valent Pneumococcal Conjugate Vaccine (20vPnC) / PF-06482077",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "dose",
            "description": "Single injection"
          }
        ],
        "durationDescription": "1 day"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Comparator / Placebo",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "dose",
            "description": "Matching active vaccine"
          }
        ],
        "durationDescription": "1 day"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_10",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "or sponsor include, but are not limited to, failure to meet entrance criteria (screening failure), AE, death, pregnancy, protocol deviation, lost to follow-up, no longer willing to participate in the "
      },
      {
        "id": "visit_3",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "6.1.2. Cohort 1: Visit 2 (Vaccination 2 – 28 to 42 Days After Visit 1)................41 6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42"
      },
      {
        "id": "visit_4",
        "visitName": "Visit 3",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42"
      },
      {
        "id": "visit_6",
        "visitName": "Visit 4",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "6.1.4. Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact] – 168 to 196 Days After Vaccination 1).............................................................42 6.2. Cohorts 2 and 3 ....."
      },
      {
        "id": "visit_7",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "6.1.4. Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact] – 168 to 196 Days After Vaccination 1).............................................................42 6.2. Cohorts 2 and 3 ....."
      },
      {
        "id": "visit_8",
        "visitName": "Visit 23",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Subjects in Cohort 1 who received 13vPnC at Vaccination 1 will receive PPSV23 at Vaccination 2. Approximately 2000 subjects 60 through 64 years of age and 1000 subjects 65 years of age and older will "
      },
      {
        "id": "visit_11",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "establish a clinical baseline. Significant medical history, significant findings from any physical examination, if performed, and temperature measurements will be documented and recorded in the source"
      },
      {
        "id": "visit_llm_None",
        "visitName": "Unscheduled Visits",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 8,
        "epoch": "All Cohorts"
      },
      {
        "id": "visit_9",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Cohort 1",
        "sourceText": "Assign randomization number  Obtain blood sample for immunogenicity (~50 mL)c"
      },
      {
        "id": "visit_12",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "each day will be recorded in the e-diary. In the event of a fever on Day 7, temperature will be collected daily until fever has resolved (1 day of temperature <100.4F [<38.0C]) in order to collect a"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Cohort 1: Visit 2 (Vaccination 2)",
        "targetDay": 35,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 2,
        "targetWeek": 5,
        "epoch": "Cohort 1"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Cohort 1: Visit 3 (Follow-up)",
        "targetDay": 70,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "targetWeek": 10,
        "epoch": "Cohort 1"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact])",
        "targetDay": 182,
        "windowBefore": 14,
        "windowAfter": 14,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 26,
        "epoch": "Cohort 1"
      },
      {
        "id": "visit_5",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "Cohort 1: 1:1; Cohort 2: 3:1; Cohort 3: 3:1",
      "method": "Randomized, double-blind",
      "centralRandomization": true,
      "blockSize": "Not specified",
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Age",
          "categories": [
            "<49 years",
            "≥49 years"
          ],
          "isBlocking": false,
          "sourceText": "age"
        },
        {
          "id": "strat_llm_1",
          "name": "Age (Cohort 1)",
          "categories": [
            "60 through 64 years of age",
            "65 years of age and older"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Cohort Assignment (Age-based)",
          "categories": [
            "Cohort 1: ≥60 years",
            "Cohort 2: 50 through 59 years",
            "Cohort 3: 18 through 49 years"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "20-valent Pneumococcal Conjugate Vaccine (20vPnC)\nB7471007\nFinal Protocol Amendment 2, 11 February 2019\nPFIZER CONFIDENTIAL\nPage 12\nPfizer is developing a new 20-valent pneumococcal conjugate vaccine "
    }
  }
}